Episode Details
Back to Episodes
HRTX Selling All Assets: The $222M Valuation Gap
Description
HRTX stock analysis: $222M buyout sparks 162% upside β full valuation deep dive
π Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends
In this deep dive, we break down Heron Therapeutics, Inc. (HRTX) and its landmark definitive agreement to sell substantially all operating assets to CorMedix for $222.6 million in upfront consideration. With shares trading near $0.29 at just 0.53 times trailing sales against $126 million in total debt obligations, the key question for investors is whether this merger arbitrage setup unlocks a 162% base-case recovery or carries severe downside liquidation risk. Hereβs everything you need to know before making a decision on HRTX.
π― SECTIONS:
β’ Executive Summary & CorMedix M&A Acquisition Structure
β’ Commercial Drug Portfolio: ZYNRELEF, APONVIE & CINVANTI
β’ Economic Moats, Generic Headwinds & NOPAIN Act Catalysts
β’ Q3 2026 Earnings Breakdown & Balance Sheet Leverage
β’ Valuation Analysis: Merger Arbitrage & Net Asset Value (NAV)
β’ 5-Year Scenario Analysis: Base, Bull & Liquidation Cases
β’ Qualitative Scorecard & Core Risk Assessment
All the research behind this video was created using Flash by StockSentinel.ai. Flash gives viewers FREE access to investment research reports on any public company.
The FREE features include:
β
Explainer Videos
β
Audio Podcasts
β
Detailed Reports
β
Investor Presentations with full qualitative and quantitative analysis
Subscribers also unlock:
β
Best Ideas Now (6 highest-conviction picks every Saturday)
β
Portfolio Watch
β
Insider IQ (alerts on significant global insider buying activity)
β
Flash Community
Subscribe + π to never miss a stock report
DISCLAIMER: This content is for informational and educational purposes only and is not investment advice. Opinions are personal and may change. Do your own research or consult a licensed professional. StockSentinel.ai is under no obligation to update this information.
#StockAnalysis #StockMarket #Investing #Stocks #ValueInvesting #StockResearch #InvestmentAnalysis #FinancialAnalysis #HRTX #HeronTherapeutics #HRTXStock #HRTXAnalysis #HealthcareStocks #BiotechStocks #FundamentalAnalysis #ValuationAnalysis #DueDiligence #NASDAQ